Below are the most recent publications written about "Quinazolines" by people in Profiles.
-
Gallo PM, Chain RW, Xu J, Whiteman LM, Palladino A, Caricchio R, Costa-Reis P, Sullivan KE, Gallucci S. EGFR-ErbB2 dual kinase inhibitor lapatinib decreases autoantibody levels and worsens renal disease in Interferon a-accelerated murine lupus. Int Immunopharmacol. 2024 Oct 25; 140:112692.
-
Kalra R, Chen CH, Wang J, Salam AB, Dobrolecki LE, Lewis A, Sallas C, Yates CC, Gutierrez C, Karanam B, Anurag M, Lim B, Ellis MJ, Kavuri SM. Poziotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer. Cancer Res. 2022 08 16; 82(16):2928-2939.
-
Kumar BNP, Puvvada N, Rajput S, Sarkar S, Mahto MK, Yallapu MM, Pathak A, Emdad L, Das SK, Reis RL, Kundu SC, Fisher PB, Mandal M. Targeting of EGFR, VEGFR2, and Akt by Engineered Dual Drug Encapsulated Mesoporous Silica-Gold Nanoclusters Sensitizes Tamoxifen-Resistant Breast Cancer. Mol Pharm. 2018 07 02; 15(7):2698-2713.
-
Abisoye-Ogunniyan A, Lin H, Ghebremedhin A, Salam AB, Karanam B, Theodore S, Jones-Trich J, Davis M, Grizzle W, Wang H, Yates C. Transcriptional repressor Kaiso promotes epithelial to mesenchymal transition and metastasis in prostate cancer through direct regulation of miR-200c. Cancer Lett. 2018 09 01; 431:1-10.
-
Ma Z, Parris AB, Xiao Z, Howard EW, Kosanke SD, Feng X, Yang X. Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice. J Exp Clin Cancer Res. 2017 01 06; 36(1):6.
-
Karki P, Johnson J, Son DS, Aschner M, Lee E. Transcriptional Regulation of Human Transforming Growth Factor-a in Astrocytes. Mol Neurobiol. 2017 03; 54(2):964-976.
-
Lekic T, Krafft PR, Klebe D, Rolland WB, Flores J, Tang J, Zhang JH. Cyclooxygenase-2 Inhibition Provides Lasting Protection Following Germinal Matrix Hemorrhage in Premature Infant Rats. Acta Neurochir Suppl. 2016; 121:203-7.
-
Godugu C, Doddapaneni R, Patel AR, Singh R, Mercer R, Singh M. Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma. Pharm Res. 2016 Jan; 33(1):137-54.
-
Samuel T, Fadlalla K, Gales DN, Putcha BD, Manne U. Variable NF-?B pathway responses in colon cancer cells treated with chemotherapeutic drugs. BMC Cancer. 2014 Aug 18; 14:599.
-
Lammers PE, Lovly CM, Horn L. A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer. J Natl Compr Canc Netw. 2014 Jan; 12(1):6-11; quiz 11.